BridgeBio has significantly improved its course of an innovative therapy for amyloid heart disease, employing the compound. Early clinical results suggests promising outcomes for individuals suffering from this serious condition. This focus represents the company’s focus to addressing critical healthcare needs in the heart disease field. Attruby